Dana Rizk MD
Professor, Medicine, University of Alabama School of Medicine Director of Clinical Trials Research, Nephrology division Medical Director of Clinical Trials Administrative Office, UAB
Join to View Full Profile
1717 6th Ave SBirmingham, AL 35233
Phone+1 800-822-8816
Fax+1 205-934-1879
Dr. Rizk is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Dana Rizk is a nephrologist in Birmingham, AL and is affiliated with multiple hospitals in the area, including Birmingham Veterans Affairs Medical Center and UAB Hospital. She received her medical degree from American University of Beirut Faculty of Medicine and has been in practice 20 years. She is experienced in general nephrology, iga nephropathy, and glomerular diseases.
Education & Training
Emory University School of MedicineFellowship, Nephrology, 2001 - 2005
SSM Health/Saint Louis University School of MedicineResidency, Internal Medicine, 1998 - 2000
American University of Beirut Faculty of MedicineClass of 1997
Certifications & Licensure
AL State Medical License 2008 - 2026
GA State Medical License 2003 - 2009
American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification HealthSentry, Cerner Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification FairWarning® Patient Privacy Monitoring, FairWarning Technologies, LLC, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification HealthSentry, Cerner Corporation, 2012, 2014, 2016-2017
Clinical Trials
- MEmbranous Nephropathy Trial Of Rituximab Start of enrollment: 2011 Nov 01
- Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease Start of enrollment: 2013 Mar 18
- FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients. Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- Humoral Response to COVID-19 Vaccines and Infection During Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial.Kieran McCafferty, Jonathan Barratt, Yusuke Suzuki, Adrian Liew, Dana V Rizk
Clinical Journal of the American Society of Nephrology. 2026-06-11 - Inhibition of p65 NF-κB enhances production of galactose-deficient IgA1 through suppression ofand SP1 in plasmablast-like cell subpopulations.Taylor Person, Maggie Phillips, Terri Rice, Stacy Hall, Bruce A Julian
Biorxiv. 2026-05-05 - The Roles of A Proliferation-Inducing Ligand (APRIL) and B-Cell Activating Factor (BAFF) in IgA Nephropathy.Colin Reily, Jan Novak, Dana V Rizk
American Journal of Kidney Diseases. 2026-05-01
Journal Articles
- Prognostic Value of Myocardial Perfusion Imaging Performed Pre-Renal Transplantation: Post-Transplantation Follow-up and OutcomesAmi E Iskandrian, Suzanne Oparil, Dana V Rizk, Christopher W Ives, Fadi G Hage, European Journal of Nuclear Medicine and Molecular Imaging
Press Mentions
Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin a Nephropathy (IgAN)June 6th, 2025- Alternative Pathway Inhibition Makes Good in IgA NephropathyOctober 26th, 2024
- FDA OKs Complement Inhibitor for IgA NephropathyAugust 8th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
